BioCina and NovaCina Announce Strategic Merger to Create Integrated CDMO

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.

Bend Bioscience Unites CoreRx and Societal CDMO Under Single Bend Bioscience Brand

September 4, 2024

Pharmaceuticals

Bend Bioscience has unified CoreRx and Societal CDMO under the Bend Bioscience brand to form an integrated contract development and manufacturing organization (CDMO). The consolidation combines CoreRx’s formulation development expertise, Societal CDMO’s scalable cGMP manufacturing and packaging capabilities, and Bend Bioscience’s research and technology to offer end-to-end development-to-commercialization services across facilities in Bend, Oregon; Clearwater, Florida; and Gainesville, Georgia.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

HAS Healthcare Advanced Synthesis Acquires Cerbios-Pharma to Form Leading CDMO Group

March 31, 2025

Healthcare Services

HAS Healthcare Advanced Synthesis SA (HAS) announced the planned acquisition of Cerbios-Pharma SA (Cerbios) to create a leading international CDMO group in Switzerland’s Ticino region. The combination brings complementary expertise in production, chemistry and biology, enabling expanded development and manufacturing services (including ADC-related capabilities), supported by 65 Equity Partners.

Chroma Medicine and Nvelop Therapeutics Merge to Form nChroma Bio

December 11, 2024

Biotechnology

Chroma Medicine and Nvelop Therapeutics have merged to form nChroma Bio and completed an oversubscribed $75 million financing led by Cormorant Asset Management, ARCH Venture Partners, Atlas Venture and Newpath Partners. The combined company will advance a pipeline built on epigenetic editing and non-viral, programmable in vivo delivery, with lead candidate CRMA-1001 targeted at chronic hepatitis B and D and a planned clinical trial application submission in 2025.

Keensight-backed Biovian and 3P Biopharmaceuticals Merge to Form 3PBIOVIAN

February 1, 2024

Biotechnology

Biovian and 3P Biopharmaceuticals have combined under their common shareholder Keensight Capital to form 3PBIOVIAN, a pan‑European biologics CDMO offering end‑to‑end development and manufacturing across microbial and mammalian protein expression, viral vectors, cell therapy and plasmid DNA. The combined group will operate sites in Pamplona‑Noáin (Spain) and Turku (Finland), maintain a commercial office in Boston, and employ over 500 professionals with gross sales above €75m; ERES IV (advised by Elyan Partners) and Sodena will remain minority shareholders alongside Keensight.